![Fiona Lawrence](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fiona Jane Lawrence is currently the VP-Clinical Development & Regulatory Affairs at Arecor Therapeutics Plc.
Previously, she worked as the Director-Research & Clinical Development at Duchenne UK, Senior Manager-Clinical Research at Prosensa Therapeutics BV, Commercial Trials Manager at Cambridge University Hospitals NHS Foundation Trust, and Senior Manager-Clinical Research at BioMarin Nederland BV.
Ms. Lawrence has an undergraduate degree from the University of Bath and a graduate degree from the University of Surrey.
| Sociétés | Poste | Début |
|---|---|---|
| ARECOR THERAPEUTICS PLC | Conseiller Juridique Général | - |
| Sociétés | Poste | Fin |
|---|---|---|
Cambridge University Hospitals NHS Foundation Trust
 Cambridge University Hospitals NHS Foundation Trust Hospital/Nursing ManagementHealth Services Operates hospitals that provides cardiology, cancer, pediatric and radiology services | Corporate Officer/Principal | - |
BioMarin Nederland BV
 BioMarin Nederland BV The company is based in Amsterdam, the Netherlands. The Dutch company focuses on creating therapies—including gene therapies, biologics, small molecules, and antisense oligonucleotides—that target the underlying genetic causes of conditions such as phenylketonuria (PKU), mucopolysaccharidosis (MPS), neuronal ceroid lipofuscinosis type 2 (CLN2), alpha-1 antitrypsin deficiency (AATD), and Duchenne muscular dystrophy (DMD). BioMarin has developed eight approved medicines and maintains a pipeline of clinical and preclinical candidates across multiple therapeutic areas, including central nervous system, cardiovascular, musculoskeletal/metabolic, and non-oncology hematology. The company operates biologics and gene therapy manufacturing facilities certified for environmental and occupational health standards. Its website provides healthcare professionals in the EU with scientific publications, product and pipeline information, clinical trial listings, and resources for medical inquiries, adverse event reporting, and product complaints. BioMarin Nederland BV is the Dutch branch of BioMarin Pharmaceutical Inc., a biotechnology company founded in 1997 that specializes in developing medicines for serious, life-threatening genetic and rare diseases. | Corporate Officer/Principal | - |
Prosensa Therapeutics BV
 Prosensa Therapeutics BV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company | Corporate Officer/Principal | - |
Duchenne UK
 Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Operates as charitable trust to fund and accelerate treatments and cure for muscular dystrophy | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 7 |
|---|---|
University of Bath
 University of Bath Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Surrey
 University of Surrey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prosensa Therapeutics BV
Prosensa Therapeutics BV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company | Health Technology |
Cambridge University Hospitals NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust Hospital/Nursing ManagementHealth Services Operates hospitals that provides cardiology, cancer, pediatric and radiology services | Health Services |
BioMarin Nederland BV
BioMarin Nederland BV The company is based in Amsterdam, the Netherlands. The Dutch company focuses on creating therapies—including gene therapies, biologics, small molecules, and antisense oligonucleotides—that target the underlying genetic causes of conditions such as phenylketonuria (PKU), mucopolysaccharidosis (MPS), neuronal ceroid lipofuscinosis type 2 (CLN2), alpha-1 antitrypsin deficiency (AATD), and Duchenne muscular dystrophy (DMD). BioMarin has developed eight approved medicines and maintains a pipeline of clinical and preclinical candidates across multiple therapeutic areas, including central nervous system, cardiovascular, musculoskeletal/metabolic, and non-oncology hematology. The company operates biologics and gene therapy manufacturing facilities certified for environmental and occupational health standards. Its website provides healthcare professionals in the EU with scientific publications, product and pipeline information, clinical trial listings, and resources for medical inquiries, adverse event reporting, and product complaints. BioMarin Nederland BV is the Dutch branch of BioMarin Pharmaceutical Inc., a biotechnology company founded in 1997 that specializes in developing medicines for serious, life-threatening genetic and rare diseases. | |
Duchenne UK
Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Operates as charitable trust to fund and accelerate treatments and cure for muscular dystrophy | Miscellaneous |
Arecor Therapeutics Plc
 Arecor Therapeutics Plc Pharmaceuticals: MajorHealth Technology Develops therapeutic products in diabetes | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
